Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J GIRARD

Showing results (581-590 of 602) with videos related to

Pageof 61
Sort By:
Bioengineering & Translational Medicine|November 18, 2024
Versatile tissue-injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeuticsEric S Nealy, Steven J Reed, Steven M Adelmund, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregationJohn J Parlow, Mary W Burney, Brenda L Case, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Functional genomic analysis of adult and pediatric brain tumor isolatesPia Hoellerbauer, Matt C Biery, Sonali Arora, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complexMichael S South, Brenda L Case, Rhonda S Wood, et al.
Genes & Development|May 9, 2013
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5AChristopher G Hubert, Robert K Bradley, Yu Ding, et al.
Science Translational Medicine|May 18, 2022
Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engagerZachary R Crook, Emily J Girard, Gregory P Sevilla, et al.
Journal of Medicinal Chemistry|September 5, 2003
Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complexJohn J Parlow, Brenda L Case, Thomas A Dice, et al.
Physics Letters. [Part B]|November 19, 1987
Exclusive measurements of mean pion multiplicities in 4He-nucleus reactions from 200 to 800 MeV/nucleonD L'Hôte, J P Alard, J Augerat, et al.
Science Translational Medicine|March 6, 2020
A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposureMichelle L Cook Sangar, Emily J Girard, Gene Hopping, et al.
Frontiers in Oncology|March 20, 2023
<i>In vivo</i> loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymomaJacqueline P Whitehouse, Hilary Hii, Chelsea Mayoh, et al.
Pageof 61

Showing results (581-590 of 602) with videos related to

Sort By:
Pageof 61
Bioengineering & Translational Medicine|November 18, 2024
Versatile tissue-injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeuticsEric S Nealy, Steven J Reed, Steven M Adelmund, et al.
Bioorganic & Medicinal Chemistry Letters|January 26, 2010
Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregationJohn J Parlow, Mary W Burney, Brenda L Case, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Functional genomic analysis of adult and pediatric brain tumor isolatesPia Hoellerbauer, Matt C Biery, Sonali Arora, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complexMichael S South, Brenda L Case, Rhonda S Wood, et al.
Genes & Development|May 9, 2013
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5AChristopher G Hubert, Robert K Bradley, Yu Ding, et al.
Science Translational Medicine|May 18, 2022
Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engagerZachary R Crook, Emily J Girard, Gregory P Sevilla, et al.
Journal of Medicinal Chemistry|September 5, 2003
Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complexJohn J Parlow, Brenda L Case, Thomas A Dice, et al.
Physics Letters. [Part B]|November 19, 1987
Exclusive measurements of mean pion multiplicities in 4He-nucleus reactions from 200 to 800 MeV/nucleonD L'Hôte, J P Alard, J Augerat, et al.
Science Translational Medicine|March 6, 2020
A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposureMichelle L Cook Sangar, Emily J Girard, Gene Hopping, et al.
Frontiers in Oncology|March 20, 2023
<i>In vivo</i> loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymomaJacqueline P Whitehouse, Hilary Hii, Chelsea Mayoh, et al.
Pageof 61